GlassScriptPhysician profile
Fariba K Pfitzner
NPI 1053511923
$4,849.81
in general payments reported to CMS, 2019-2025
25 companies · $636 in 2025
The $636 reported for 2025 was more than what 79% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $622 · 2021: $486 · 2022: $728 · 2023: $862 · 2024: $814 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288 · Education: $24.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.78 |
| Education | $24.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $975.78 | 2021-2025 | Caplyta |
| Abbvie INC. | $621.06 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $516.44 | 2019-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $502.79 | 2019-2025 | Spravato |
| Alkermes, INC. | $476.16 | 2019-2024 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $279.24 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $261.97 | 2019-2023 | Austedo |
| Novo Nordisk INC | $242.85 | 2025 | Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $228.04 | 2020-2021 | |
| Axsome Therapeutics, INC. | $147.15 | 2024 | Auvelity |
| Neos Therapeutics, LP | $96.11 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Eisai INC. | $82.44 | 2020-2021 | |
| Alfasigma USA, INC. | $71.81 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $45.99 | 2020-2022 | |
| Vertical Pharmaceuticals, LLC | $40.67 | 2025 | Relexxii |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $39.55 | 2022 | |
| Indivior INC. | $38.16 | 2020 | |
| Supernus Pharmaceuticals, INC. | $34.07 | 2021-2023 | Qelbree |
| Neuronetics, INC. | $30.15 | 2025 | Neurostar Tms Therapy System |
| Ironshore Pharmaceuticals INC. | $24.18 | 2020 | |
| Edwards Lifesciences Corporation | $21.40 | 2025 | Sapien 3 Ultra Resilia |
| Corium, LLC | $20.33 | 2023 | Azstarys |
| Shire North American Group INC | $19.96 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.51 | 2020 | |
| Noven Therapeutics, LLC | $16.00 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariba Pfitzner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.